WEKO3
アイテム
{"_buckets": {"deposit": "e447ec72-51a5-4422-893c-ab90edeff223"}, "_deposit": {"created_by": 2, "id": "15149", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "15149"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00015149", "sets": ["9"]}, "author_link": ["55673", "55667", "55670", "55666", "55668", "55669", "55672", "55675", "55676", "55671", "55674"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "762", "bibliographicPageStart": "757", "bibliographicVolumeNumber": "54", "bibliographic_titles": [{"bibliographic_title": "Antimicrobial agents and chemotherapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Clarithromycin is a 14-member lactone ring macrolide with potent activity against Haemophilus influenzae, including ampicillin-resistant strains. We evaluated the in vivo efficacy of clarithromycin at 40 mg/day and 100 mg/day for 3 days in the treatment of a murine model of pneumonia using a macrolide-resistant H. influenzae strain, which was also ampicillin resistant. The MIC of clarithromycin was 64 microg/ml. The viable bacterial counts in infected tissues after treatment with 100 mg clarithromycin/kg of body weight were lower than the counts obtained in control and 40-mg/kg clarithromycin-treated mice. The concentrations of macrophage inflammatory protein 2 (MIP-2) and interleukin 1beta (IL-1beta) in bronchoalveolar lavage fluid (BALF) samples from mice treated at both concentrations were lower than in the control group. Pathologically, following infection, clarithromycin-treated mice, particularly at a dose of 100 mg/kg, showed lower numbers of neutrophils in alveolar walls, and inflammatory changes had apparently improved, whereas large aggregates of inflammatory cells were observed within the alveoli of control mice. In addition, we demonstrated that clarithromycin has bacteriological effects against intracellular bacteria at levels below the MIC. Our results indicate that clarithromycin may be useful in vivo for macrolide-resistant H. influenzae, and this phenomenon may be related to the good penetration of clarithromycin into bronchoepithelial cells. We also believe that conventional drug susceptibility tests may not reflect the in vivo effects of clarithromycin.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Antimicrobial agents and chemotherapy, 54(2), pp.757-762; 2010", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "American Society for Microbiology"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "19949056", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1128/AAC.00524-09", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © 2010, American Society for Microbiology. All Rights Reserved."}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00542574", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00664804", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1098-6596", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Shigeki"}], "nameIdentifiers": [{"nameIdentifier": "55666", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yanagihara, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "55667", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Araki, Nobuko"}], "nameIdentifiers": [{"nameIdentifier": "55668", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "55669", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morinaga, Yoshitomo"}], "nameIdentifiers": [{"nameIdentifier": "55670", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izumikawa, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "55671", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Seki, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "55672", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kakeya, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "55673", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Yoshihiro"}], "nameIdentifiers": [{"nameIdentifier": "55674", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamihira, Shimeru"}], "nameIdentifiers": [{"nameIdentifier": "55675", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "55676", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "AAC54_757.pdf", "filesize": [{"value": "383.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 383600.0, "url": {"label": "AAC54_757.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/15149/files/AAC54_757.pdf"}, "version_id": "2dea3362-4ad1-47cd-8f79-d138d5739839"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice."}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/23025", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-03-01"}, "publish_date": "2010-03-01", "publish_status": "0", "recid": "15149", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice."], "weko_shared_id": 2}
Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.
http://hdl.handle.net/10069/23025
http://hdl.handle.net/10069/23025bf198e0d-2dc0-4325-8f73-106e88409475
名前 / ファイル | ライセンス | アクション |
---|---|---|
AAC54_757.pdf (383.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-03-01 | |||||
タイトル | ||||||
タイトル | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Nakamura, Shigeki
× Nakamura, Shigeki× Yanagihara, Katsunori× Araki, Nobuko× Yamada, Koichi× Morinaga, Yoshitomo× Izumikawa, Koichi× Seki, Masafumi× Kakeya, Hiroshi× Yamamoto, Yoshihiro× Kamihira, Shimeru× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Clarithromycin is a 14-member lactone ring macrolide with potent activity against Haemophilus influenzae, including ampicillin-resistant strains. We evaluated the in vivo efficacy of clarithromycin at 40 mg/day and 100 mg/day for 3 days in the treatment of a murine model of pneumonia using a macrolide-resistant H. influenzae strain, which was also ampicillin resistant. The MIC of clarithromycin was 64 microg/ml. The viable bacterial counts in infected tissues after treatment with 100 mg clarithromycin/kg of body weight were lower than the counts obtained in control and 40-mg/kg clarithromycin-treated mice. The concentrations of macrophage inflammatory protein 2 (MIP-2) and interleukin 1beta (IL-1beta) in bronchoalveolar lavage fluid (BALF) samples from mice treated at both concentrations were lower than in the control group. Pathologically, following infection, clarithromycin-treated mice, particularly at a dose of 100 mg/kg, showed lower numbers of neutrophils in alveolar walls, and inflammatory changes had apparently improved, whereas large aggregates of inflammatory cells were observed within the alveoli of control mice. In addition, we demonstrated that clarithromycin has bacteriological effects against intracellular bacteria at levels below the MIC. Our results indicate that clarithromycin may be useful in vivo for macrolide-resistant H. influenzae, and this phenomenon may be related to the good penetration of clarithromycin into bronchoepithelial cells. We also believe that conventional drug susceptibility tests may not reflect the in vivo effects of clarithromycin. | |||||
書誌情報 |
Antimicrobial agents and chemotherapy 巻 54, 号 2, p. 757-762, 発行日 2010-02 |
|||||
出版者 | ||||||
出版者 | American Society for Microbiology | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00664804 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1098-6596 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00542574 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 19949056 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1128/AAC.00524-09 | |||||
権利 | ||||||
権利情報 | Copyright © 2010, American Society for Microbiology. All Rights Reserved. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Antimicrobial agents and chemotherapy, 54(2), pp.757-762; 2010 |